Slingshot Insights | Edit Overview

EDIT Overview

Upcoming Projects (EDIT)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (EDIT)

Discussing the IPSC and NK cell infusion landscape in the oncology space with a focus on technologies in development by Editas and Fate Therapeutics
Tickers: FATE, EDIT
Executed On: Jan 19, 2022 at 02:00 PM EST

Expired Projects (EDIT)

An in-depth look at the Gene Therapy Landscape
Tickers: VRTX, BLUE, ONCE, CRSP, EDIT, NTLA
Execute By: Dec 31, 2021

Upcoming & Overdue Catalysts (EDIT)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (EDIT)

Editas Medicine (EDIT) Reports Preclinical Data in Tumor Reduction And Clearance Using Novel, Engineered INK Cells At The American Society Of Hematology Annual Meeting
Ticker: EDIT
Occurred on: Dec 12, 2021
Editas Medicine (EDIT) plans to submit IND application for LCA10, a vaccine for eye disease,in the middle of 2018
Ticker: EDIT
Occurred on: Nov 30, 2018
Editas Medicine (EDIT) to initiate natural history trial LCA10, a vaccine for eye disease, in the middle of 2017
Ticker: EDIT
Occurred on: Aug 09, 2017
Editas Medicine Announces Initial Public Offering of 5,900,000 shares at a public offering price of $16.00 per share; trading expected to begin on Wednesday, February 3, 2016 under the ticker symbol “EDIT.”
Ticker: EDIT
Occurred on: Feb 03, 2016

Strategic Initiatives (EDIT)

Editas Medicine (EDIT) enters agreement with Sandhill Therapeutics to develop allogeneic engineered natural killer (NK) cells and non-alpha beta T cell medicines for the treatment of cancer
Ticker: EDIT
Announcement Date: Jan 13, 2020
Allergan (AGN) Announces Exclusive R&D Partnership with Editas (EDIT) for Five Gene-Editing Ocular Programs
Tickers: AGN, EDIT
Announcement Date: Mar 14, 2017